๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Overview of safety of non-biologic and biologic DMARDs

โœ Scribed by Ruderman, E. M.


Book ID
119975247
Publisher
Oxford University Press
Year
2012
Tongue
English
Weight
86 KB
Volume
51
Category
Article
ISSN
1462-0324

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


OVERVIEW OF BIOLOGIC FACTORS
โœ Silk, Kenneth R. ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 980 KB
Safety of biologic therapy
โœ Wojciech Blonski; Gary R. Lichtenstein ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 207 KB

Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and mai